Vericiguat: A Randomized, Phase Ib, Placebo-Controlled, Double-Blind, QTc Interval Study in Patients with Chronic Coronary Syndromes.
Saved in:
| Title: | Vericiguat: A Randomized, Phase Ib, Placebo-Controlled, Double-Blind, QTc Interval Study in Patients with Chronic Coronary Syndromes. |
|---|---|
| Authors: | Böttcher M; Clinical Pharmacology, Bayer AG, Wuppertal, Germany., Düngen HD; Department of Internal Medicine, Cardiology, Charité-Universitaetsmedizin Berlin, Berlin, Germany., Corcea V; Department of Cardiac Surgery, PMSI Clinical Republican Hospital 'T. Mosneaga', Chisinau, Republic of Moldova., Donath F; SocraTec R&D GmbH, Erfurt, Germany., Fuhr R; Early Phase Clinical Unit, Parexel, Berlin, Germany., Gal P; Centre for Human Drug Research, Leiden, The Netherlands.; Clinical Pharmacology and Toxicology Department, Leiden University Medical Center, Leiden, The Netherlands., Mikus G; Department of Clinical Pharmacology and Pharmacoepidemiology, University Hospital Heidelberg, Heidelberg, Germany., Trenk D; Department University Heart Center Campus Bad Krozingen, Clinics of Cardiology and Angiology-Clinical Pharmacology, University Medical Center Freiburg, Freiburg, Germany., Coenen M; Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany., Pires PV; Research and Development, Bayer AG, Wuppertal, Germany., Maschke C; Study Management, Bayer AG, Wuppertal, Germany., Aliprantis AO; Translational Medicine, Merck & Co., Inc., Rahway, New Jersey, USA.; Pioneering Medicines, Flagship Pioneering, Boston, Massachusetts, USA., Besche N; Chrestos Concept GmbH & Co. KG, Essen, Germany., Becker C; Clinical Pharmacology, Bayer AG, Wuppertal, Germany. corina.becker@bayer.com. |
| Source: | American journal of cardiovascular drugs : drugs, devices, and other interventions [Am J Cardiovasc Drugs] 2023 Mar; Vol. 23 (2), pp. 145-155. Date of Electronic Publication: 2023 Jan 12. |
| Publication Type: | Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase I; Journal Article |
| Journal Info: | Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 100967755 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-187X (Electronic) Linking ISSN: 11753277 NLM ISO Abbreviation: Am J Cardiovasc Drugs Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 36633816 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Vericiguat: A Randomized, Phase Ib, Placebo-Controlled, Double-Blind, QTc Interval Study in Patients with Chronic Coronary Syndromes. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Böttcher+M%22">Böttcher M</searchLink>; Clinical Pharmacology, Bayer AG, Wuppertal, Germany.<br /><searchLink fieldCode="AU" term="%22Düngen+HD%22">Düngen HD</searchLink>; Department of Internal Medicine, Cardiology, Charité-Universitaetsmedizin Berlin, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Corcea+V%22">Corcea V</searchLink>; Department of Cardiac Surgery, PMSI Clinical Republican Hospital 'T. Mosneaga', Chisinau, Republic of Moldova.<br /><searchLink fieldCode="AU" term="%22Donath+F%22">Donath F</searchLink>; SocraTec R&D GmbH, Erfurt, Germany.<br /><searchLink fieldCode="AU" term="%22Fuhr+R%22">Fuhr R</searchLink>; Early Phase Clinical Unit, Parexel, Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Gal+P%22">Gal P</searchLink>; Centre for Human Drug Research, Leiden, The Netherlands.; Clinical Pharmacology and Toxicology Department, Leiden University Medical Center, Leiden, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Mikus+G%22">Mikus G</searchLink>; Department of Clinical Pharmacology and Pharmacoepidemiology, University Hospital Heidelberg, Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Trenk+D%22">Trenk D</searchLink>; Department University Heart Center Campus Bad Krozingen, Clinics of Cardiology and Angiology-Clinical Pharmacology, University Medical Center Freiburg, Freiburg, Germany.<br /><searchLink fieldCode="AU" term="%22Coenen+M%22">Coenen M</searchLink>; Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany.<br /><searchLink fieldCode="AU" term="%22Pires+PV%22">Pires PV</searchLink>; Research and Development, Bayer AG, Wuppertal, Germany.<br /><searchLink fieldCode="AU" term="%22Maschke+C%22">Maschke C</searchLink>; Study Management, Bayer AG, Wuppertal, Germany.<br /><searchLink fieldCode="AU" term="%22Aliprantis+AO%22">Aliprantis AO</searchLink>; Translational Medicine, Merck & Co., Inc., Rahway, New Jersey, USA.; Pioneering Medicines, Flagship Pioneering, Boston, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Besche+N%22">Besche N</searchLink>; Chrestos Concept GmbH & Co. KG, Essen, Germany.<br /><searchLink fieldCode="AU" term="%22Becker+C%22">Becker C</searchLink>; Clinical Pharmacology, Bayer AG, Wuppertal, Germany. corina.becker@bayer.com. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22100967755%22">American journal of cardiovascular drugs : drugs, devices, and other interventions</searchLink> [Am J Cardiovasc Drugs] 2023 Mar; Vol. 23 (2), pp. 145-155. <i>Date of Electronic Publication: </i>2023 Jan 12. – Name: TypePub Label: Publication Type Group: TypPub Data: Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase I; Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Adis%2C+Springer+International%22">Adis, Springer International </searchLink><i>Country of Publication: </i>New Zealand <i>NLM ID: </i>100967755 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1179-187X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2211753277%22">11753277 </searchLink><i>NLM ISO Abbreviation: </i>Am J Cardiovasc Drugs <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36633816 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1007/s40256-022-00557-2 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 145 Titles: – TitleFull: Vericiguat: A Randomized, Phase Ib, Placebo-Controlled, Double-Blind, QTc Interval Study in Patients with Chronic Coronary Syndromes. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Böttcher M – PersonEntity: Name: NameFull: Düngen HD – PersonEntity: Name: NameFull: Corcea V – PersonEntity: Name: NameFull: Donath F – PersonEntity: Name: NameFull: Fuhr R – PersonEntity: Name: NameFull: Gal P – PersonEntity: Name: NameFull: Mikus G – PersonEntity: Name: NameFull: Trenk D – PersonEntity: Name: NameFull: Coenen M – PersonEntity: Name: NameFull: Pires PV – PersonEntity: Name: NameFull: Maschke C – PersonEntity: Name: NameFull: Aliprantis AO – PersonEntity: Name: NameFull: Besche N – PersonEntity: Name: NameFull: Becker C IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 03 Text: 2023 Mar Type: published Y: 2023 Identifiers: – Type: issn-electronic Value: 1179-187X Numbering: – Type: volume Value: 23 – Type: issue Value: 2 Titles: – TitleFull: American journal of cardiovascular drugs : drugs, devices, and other interventions Type: main |
| ResultId | 1 |